Still early to define a clear role of antimalarial drugs for COVID-19 in patients with rheumatic disease. Response to: 'Hydroxychloroquine reduces the risk of covid-19 in patients with rheumatic diseases: myth or reality?' by Xie et al.
Carmen Magdalena Gamboa-AlonsoGabriel Figueroa-ParraDionicio Ángel Galarza-DelgadoPublished in: Annals of the rheumatic diseases (2020)